

**This item is the archived peer-reviewed author-version of:**

Adverse reactions to illicit drugs (marijuana, opioids, cocaine) and alcohol

**Reference:**

Decuyper Ine, Armentia Alicia, Martin-Armentia Blanca, Corell Almuzara Alfredo, Ebo Didier, Brucker Hannelore A..- Adverse reactions to illicit drugs (marijuana, opioids, cocaine) and alcohol  
The journal of allergy and clinical immunology. In practice- ISSN 2213-2201 - 9:8(2021), p. 3006-3014  
Full text (Publisher's DOI): <https://doi.org/10.1016/J.JAIP.2021.04.061>  
To cite this reference: <https://hdl.handle.net/10067/1816110151162165141>

# Adverse reactions to illicit drugs (marijuana, opioids, cocaine) and alcohol

Ine I. Decuyper, MD, PhD<sup>1,\*</sup>, Alicia Armentia, MD, PhD<sup>2,\*</sup>, Blanca Martín-Armentia<sup>2</sup>, Alfredo Corell Almuzara MD, PhD<sup>3</sup>, Didier G. Ebo, MD, PhD<sup>4</sup>, Hannelore A. Brucker, MD<sup>5</sup>

*\* authors contributed equally*

<sup>1</sup> *Department of Pediatrics, University Hospital of Antwerp, Antwerp University, Antwerp, Belgium*

<sup>2</sup> *Allergy Service, Hospital Universitario Río Hortega. Valladolid University. Spain*

<sup>3</sup> *Immunology Department. Valladolid University. Spain*

<sup>4</sup> *Infla-Med, University of Antwerp, Department of Immunology-Allergology-Rheumatology, University Hospital of Antwerp/University of Antwerp, Antwerp, Belgium.*

<sup>5</sup> *Southdale Allergy and Asthma Clinic, LLC, Minneapolis, MN USA*

ORCID:

Decuyper I.I. 0000-0001-8127-5791, Armentia A. 0000-0002-4165-4305, Blanca Martín-Armentia 0000-0003-2110-7395, Alfredo Corell Almuzara 0000-0001-5797-7814, Ebo Didier Gaston 0000-0003-0672-7529, Brucker Hannelore A. 0000-0003-3039-7742

**Key words:** marijuana, cocaine, heroin, opium, anaphylaxis, drug allergy, drug-abuse, anesthesia, alcohol, Analgesia; Anaphylaxis; Opioids; *Papaver somniferum*, *Cannabis sativa*

22 ABBREVIATIONS

23

24

25 AERD Aspirin Exacerbated Respiratory Disease

26 BAL bronchial alveolar lavage

27 BAT basophil activation test

28 Bet v Betula verrucosa

29 Can s Cannabis sativa

30 CBD cannabidiol

31 CRS chronic rhinosinusitis

32 LA local anesthetics

33 LT leukotrienes

34 NSAIDs non-steroidal anti-inflammatory drugs

35 nsLTP nonspecific lipid transfer protein

36 OEEP2 oxygen-evolving enhancer protein 2

37 SPT Skin prick tests

38 sIgE specific immunoglobulin E

39 THC Tetrahydrocannabinol

40 TLCO Transfer Factor of the Lung for Carbon Monoxide

41

42 ABSTRACT

43

44 Drug allergy has been a research topic within the allergy field for decades. However, many drug reactions  
45 presumed to be of allergic nature, are not and originate from different mechanisms. Drug-induced  
46 reactions can affect numerous organ systems, present with a variety of symptoms, and have more than  
47 one mechanism of action. In this rostrum article we want to give an overview of the different allergic and  
48 non-allergic reactions that can be expected with the (illicit) use of cannabis, cocaine, opioids and alcohol.  
49 In addition, this article focuses on the different methods available to diagnose allergy related to these  
50 four drug types and highlight the pitfalls of non-allergic reactions or allergy “mimickers” complicating  
51 diagnosis of true drug allergy. Finally, the impact on current medical practices is addressed and future  
52 research in support of the allergist in diagnosis and treatment of these medical problems.

53

## 54 INTRODUCTION

55 The prevalence of drug allergy has been reported as high as 15% in hospitalized populations but to date,  
56 the prevalence of hypersensitivity to drugs of abuse is unknown.<sup>1</sup> Some drug reactions are presumed to  
57 be of an allergic nature, but closer examination may reveal that they are not. Real drug-induced reactions  
58 can affect numerous organ systems, present with a variety of symptoms, and have more than one  
59 mechanism of action.<sup>2</sup> The diagnosis of drug allergy relies on the clinical history, physical examination,  
60 skin testing, *in vitro/ex vivo* tests and drug provocation tests.<sup>3-6</sup> The problem is that in the case of adverse  
61 reactions to illicit drugs, there are no commercialized diagnostic extracts and challenges may be  
62 dangerous and can constitute legal and ethical issues.<sup>3-6</sup> This article includes a background on the topic  
63 of illicit drug allergy including cannabis, cocaine and opiates/opioids and adverse reactions to alcohol. It  
64 focuses on the impact on current medical practices and future research in support of the allergist in  
65 diagnosis and treatment of these medical problems.

66

67

## 68 CANNABIS ALLERGY

69 Cannabis is an illicit drug derived from the flower tops of the cannabis plant, mostly the *sativa* or *indica*  
70 varieties. Its preparations are otherwise known as 'weed', 'hash' or marijuana and are the most  
71 widespread (ab)used drugs throughout the world (see figure 1).<sup>7</sup>

72 The active ingredients are called cannabinoids, of which delta-9-tetrahydrocannabinol (THC) and  
73 cannabidiol (CBD) are the most well-known. THC is (ab)used mainly in a recreational setting for its  
74 psychoactive effects. However, there is an increasing trend in decriminalizing and even legalizing THC-  
75 rich cannabis use around the world allowing for use in a medical setting as an antispasmodic, analgesic,  
76 anxiolytic and anti-emetic drug.<sup>8</sup> On the other hand, CBD has grown in popularity for a variety of benefits,  
77 some more evidence-based than others. One of the best documented benefits is found to be its anti-  
78 epileptic activity in otherwise therapy resistant Dravet and Lennox-Gastaut syndromes.<sup>9</sup> Although

79 research has proven that cannabis and its components can be of significant use in medical applications,  
80 certain dangers and adverse effects cannot be excluded when its use is uncontrolled, such as is seen  
81 when the drug is used recreationally.<sup>10</sup> Cannabis allergy is one of these adverse effects. Although  
82 research on the topic is still in its infancy, and the prevalence of such an allergy remains unknown,  
83 different research groups around the world have shown that a cannabis allergy can manifest severe and  
84 generalized symptoms with detrimental effects on a patient's health and quality of life.<sup>11-14</sup> As such, in this  
85 article we aim to describe cannabis allergy and discuss the difficulty discriminating "allergic" symptoms  
86 from physiological effects, as well as the challenges associated with diagnosis, and finally debate  
87 possible future diagnosis and treatment options.

88

#### 89 **Physiological effects or allergic symptoms of cannabis?**

90 Although we now know that cannabis allergy exists and can express a variety of symptoms (Figure 2), it  
91 can remain challenging to differentiate symptoms mediated by a hypersensitivity reaction from "normal"  
92 cannabis effects for several reasons.

93 First of all, it has been shown that both cannabis smoking and gastrointestinal consumption, can induce  
94 a conjunctival injection quite similar to what is seen in allergic rhino-conjunctivitis, even if the subject is  
95 not sensitized to cannabis.<sup>15</sup> Multiple pulmonological investigations have discussed cannabis' effects on  
96 the bronchi showing that short term effects could induce bronchodilation,<sup>16</sup> whereas chronic use is more  
97 often linked to bronchoconstriction which can be hard to clinically differentiate from asthma/allergy.<sup>17 18</sup>  
98 Multiple reports stemming from occupational cannabis exposure have suggested that cutaneous  
99 cannabis contact and/or contact with the chemical pesticides used in plantations, can induce an irritating  
100 reaction<sup>19 20</sup> that can be confused with allergic contact urticaria and/or eczema as seen in cannabis  
101 allergic reactions.<sup>11 19-24</sup>

102

## Diagnostic challenges for cannabis allergy

As with most allergies, a diagnosis of cannabis allergy should firstly be based on a detailed history and would ideally include a challenge test. The latter is currently a big hurdle for multiple reasons. For one, in most countries cannabis is still banned thus making challenge tests illegal. Secondly, the physiological effects of cannabis can cloud the interpretation of the challenge as inhaled cannabis can cause (rhino)conjunctivitis and affect the bronchi (constriction/dilatation depending on cited research)<sup>18 25 26</sup>. Finally, the drug induces a mind-altering state complicating the patient's symptom assessment and recollection of experienced symptoms. The lion's share of reports on cannabis allergy make note of an IgE-mediated allergy that has been linked to different allergenic components (see table 1) such as Can s 3 and Can s 4 (OEEP2) and more recently also Can s 2 (Cs-profilin) and Can s 5 (Cs-Bet v 1 homologue).<sup>14 27-29</sup> As some of these allergens belong to a superfamily of panallergens including the nsLTP family (nonspecific lipid-transfer proteins), profilins and Bet v 1 homologues, cannabis allergic patients can experience cross-allergies with multiple plant-foods and *Hevea latex*.<sup>11 12 28 30</sup> This type of cannabis allergy can be diagnosed with different allergy diagnostics, such as skin prick tests (SPTs), specific (s)IgE quantification and basophil activation tests (BATs), using crude extracts or purified/recombinant proteins.<sup>31</sup> As can be expected, test specificity seems to be best using recombinant allergens<sup>11 13 32</sup>, whereas sensitivity is found to be superior when using crude cannabis extracts. However, when using the latter, it is important to keep in mind that a significant number of pollen-sensitized individuals can exhibit clinically irrelevant results.<sup>11</sup> Anyhow, as the scientific exploration of cannabis allergy has only just begun, there are no standardized and validated tests on the market as of yet. There is a sIgE hemp (ImmunoCAP) available from Phadia, Thermo Fisher but for research purposes only. So, when there is a clinical suspicion of a cannabis allergy case, as illustrated by the diagnostic algorithm in figure 2, we would pragmatically suggest performing SPT/sIgE with a crude extract (preferably from the patient's own cannabis materials) as false negatives are expected to be few, and further confirmation with component resolved diagnostics can follow, if available.<sup>31</sup>

128 When it comes to IgE-independent cannabis allergies, to our knowledge only one report has looked into  
129 a type 4 hypersensitivity reaction causing contact dermatitis.<sup>33</sup> Finally, in the occupational cannabis  
130 setting there is a well-documented body of evidence indicating that cannabis-induced byssinosis can  
131 occur; a form of occupational asthma attributed to organic dust exposure, derived in part from naturally  
132 occurring microorganisms.<sup>34</sup> Diagnosis of byssinosis starts with a detailed history as symptoms are often  
133 solely respiratory, are worst on the first day of exposure, diminish the following days and re-emerge after  
134 a period of non-exposure. In addition, spirometry is a helpful tool to objectify cannabis-related  
135 bronchoconstriction. A CT-scan (millimetric) can further aid in the diagnosis of byssinosis and other types  
136 of pneumonitis as can fluids obtained during bronchoscopy (bronchial alveolar lavage or BAL) and lung  
137 diffusion tests such as TLCO.

138

## 139 **Prospects for the future**

140 The current evidence has established that IgE-mediated cannabis allergy is a true allergy entity which  
141 can manifest severe and generalized symptoms with a variety of cross-reactivities. Nevertheless,  
142 prediction of its prevalence remains difficult, in part because of the illegal status of the drug and thus the  
143 impact of cannabis allergy on society should still be further explored. In addition, several allergens have  
144 been detected with most recently the confirmation of Can s 2 (profilin), Can s 4 (OEEP2) and Can s 5 (a  
145 Bet v 1 homologue) as potential cannabis allergens.<sup>27 29</sup> Still, the IgE-reactivity profile seems to be  
146 incomplete and remains food for thought. Finally, for the time being there is no available cure for IgE-  
147 mediated cannabis allergy nor for the cannabis-related plant-food allergies. Therefore, strict avoidance  
148 measures remain of the utmost importance. These measures comprise a complete stop of further  
149 cannabis exposure and avoidance of exposures to allergens implicated in the individual cross-reactivity  
150 syndrome. Although some case reports claim successful desensitization<sup>35 36</sup>, further research is needed  
151 to investigate its true potential as cannabis allergy treatment.



152

153

## 154 COCAINE ALLERGY

155 Natural cocaine is an alkaloid extracted from the leaves of the coca shrub *Erythroxylum coca* and *E.*  
156 *novogranatense*. The harvested leaves are macerated with various solvents. This process results in a  
157 pasty substance (“coca paste”) which contains 80% cocaine and is purified to “coca base”. Through  
158 reaction with hydrochloric acid cocaine powder is formed while the solvents and acids are removed.  
159 Cocaine powder can be used via oral, sublingual, intravenous, intramuscular, and subcutaneous routes.  
160 The nasal use is called snorting. If cocaine hydrochloride is precipitated it can be smoked as “free-base  
161 cocaine” or “crack (rock)”.<sup>37</sup> Bronchospasm can occur in patients smoking cocaine<sup>38-40</sup>, often in patients  
162 with a history of asthma. Research has shown that cocaine use may be responsible for asthma onset,  
163 acute asthma exacerbations (which may require intubation and invasive ventilation) and asthma-related  
164 death.<sup>41</sup>

165 Smoking crack cocaine and nasal insufflation of cocaine increases the risk of emergency department  
166 visits due to severe angioedema<sup>41</sup>. Studies that investigate the prevalence of potentially harmful  
167 adulterants in crack have found that the most prevalent adulterant is lidocaine (92%), followed by  
168 phenacetin (69%) and levamisole (31%)<sup>42</sup>. The immunomodulatory adjuvant and antihelminth levamisole  
169 is increasingly used as an adulterant in cocaine worldwide. Neutropenia, agranulocytosis,  
170 leukoencephalopathy and vasculitis in cases associated with levamisole-adulterated cocaine has been  
171 described<sup>43</sup>.

172

173 In a series of 211 patients with symptoms related to cocaine abuse<sup>37</sup>, 41 were diagnosed as cocaine  
174 allergic by positive challenge, prick and sIgE to coca leaves.

175 Some local anesthetics (LA) derived from cocaine (benzocaine, dibucaine, procaine) and cases of  
176 anaphylaxis after LA have been described<sup>44 45</sup>, but overall IgE -mediated (immediate) allergy to LA is

177 rare.<sup>44</sup> The major source of delayed reactions to LAs is direct contact resulting in allergic contact  
178 dermatitis, especially by dibucaine-containing perianal medicaments<sup>46</sup>, although benzocaine has been  
179 identified as a leading sensitizer.<sup>38 40 41 45</sup>

180 Until now, as for cannabis allergy, there are no efficient commercial diagnostic techniques that  
181 demonstrate an IgE-mediated allergy to cocaine. Studies showing that cocaine-dependent patients  
182 respond positively to prick and sIgE tests to coca leaf extracts, led to investigate the use of these tests  
183 in patients with hypersensitivity to cocaine-derived LA.<sup>37</sup> Component resolved diagnosis (CRD) have also  
184 been used to determine its sensitivity and sensibility in detecting sensitivity to the different molecules of  
185 complex allergens, such as cocaine, which is often adulterated, or coca leaf extracts. Using a large  
186 database <sup>37</sup>, the study focused on patients with anaphylaxis to local anesthesia and patients with drug  
187 abuse and symptoms of asthma and anaphylaxis after cocaine use. The diagnostic yield (sensitivity,  
188 specificity, and predictive value) of allergy tests using cocaine and coca leaf (figure 1) extracts in  
189 determining cocaine allergy was assessed, taking a positive challenge as the gold standard. This  
190 research found that SPTs and sIgE to coca leaves (coca tea) had a good sensitivity and specificity for  
191 the diagnosis of cocaine allergy and local anesthetic-derived allergy.

192 In summary, cocaine allergy may provoke life-threatening symptoms and should be considered in  
193 cocaine-dependent patients with poorly controlled asthma and in candidates for surgery. Cocaine  
194 hypersensitivity may be tested with a simple and practical method such as SPTs and sIgE determination  
195 to cocaine extracts in the clinical situation. However, more research is necessary to define the exact  
196 nature of the allergic compounds and develop standardized and commercially available tests.<sup>47</sup> A  
197 correlation of such tests with serum tryptase, plasma histamine and if available, basophil activation test  
198 (BAT) would add to the validation of allergic reactions.<sup>47,48</sup>

199 ALLERGY TO OPIATES AND OPIOIDS

200 Opium is the dried sap that is drained from the seed pod of the opium plant *Papaver somniferum*.  
201 Morphine and opioid based drugs are created in refineries. A series of chemical reactions changes  
202 morphine to heroin powder (figure 1). Opioids and Opiates constitute an important part of (illicit) drug  
203 abuse but on the other hand, they are also potent analgesics of vital importance in a hospitalized setting.  
204 An important characteristic of opiates, such as morphine and codeine, is the fact that they can trigger a  
205 histamine release from skin mast cells mimicking allergic reactions. Methadone, tramadol, fentanyl and  
206 its derivatives do not have this property.<sup>49</sup> This nonspecific histamine release makes the traditional allergy  
207 SPT to opiates and (semi-)synthetic opioids difficult to interpret. It is challenging to differentiate IgE-  
208 mediated opiate allergy from non-specific reactions.

209 For several decades, case reports, retrospective studies, and laboratory investigations have  
210 demonstrated that heroin inhalation can be associated with increased asthma symptoms (possibly  
211 because of non-specific histamine release) and reduced pulmonary function. Smoking or nasal  
212 insufflation of heroin increases the risk of emergency department visits and hospitalizations for asthma.<sup>38</sup>

213 In light of the diagnostic challenges for opiates, researchers debate whether diagnostics based upon  
214 opium seed extracts are helpful. Spanish researchers have explored heroin sensitization in a cannabis  
215 allergic, multi drug addicted population, to try and prevent hypersensitivity reactions to opioids, during  
216 surgery<sup>13 32 50</sup>. To avoid the non-specific histamine release of opiates in SPTs, opium seed extracts (figure  
217 1) were used as a substitute for heroin.<sup>51</sup> Two hundred-and-three patients from said population were  
218 selected with hypersensitivity reactions during surgery, and confirmed heroin abuse. Patients sensitized  
219 to heroin (defined as a positive challenge) or with severe clinical reactions during surgery, responded to  
220 *P. somniferum* seed tests (positive IgE and skin tests). Opium seed SPTs and sIgE, especially the oil  
221 body fraction, were more sensitive (64.2%) and specific (98.4%) than morphine, codeine and rocuronium  
222 tests for opioid sensitivity. However, a Belgian group also explored sIgE to morphine and opium seed  
223 extracts additionally to BAT with morphine/codeine in 22 individuals; they found that positive sIgE results  
224 to poppy seed and morphine were not per se predictive for genuine opiate allergy. However, BAT seemed

225 promising to help discriminate clinical reactivity and sensitization.<sup>52</sup> Genuine IgE-mediated anaphylaxis  
226 to opiates and synthetic opioids (methadone, tramadol, fentanyl and its derivatives) is rare.<sup>49</sup> Little or no  
227 evidence exists between cross-reactivity of the different opioid subclasses but cross-reactivity between  
228 morphine and codeine was reported.<sup>53 54</sup> IgE and skin tests for the oil body fraction of *P. somniferum* had  
229 the highest sensitivity for sensitization to opioids. Another concept regards non-specific mediator release,  
230 likely because of occupation of the Mas-related G protein-coupled receptor X2, that is mainly expressed  
231 by skin mast cells, as much more prevalent.<sup>49 54</sup> At present there is no reliable diagnostic to document  
232 such MRGPRX2 reactions that are clinically and biologically indistinguishable from IgE-mediated  
233 reactions.<sup>55</sup> A possible diagnostic approach could include ex vivo basophil activation experiments, as  
234 these cells barely express this receptor, and do not react non-specifically to MRGPRX2 agonists.<sup>52 56</sup>

235 A major problem with illicit drugs such as heroin is that their illegal status results in varying drug  
236 compositions, ingredients, and possible contaminants. The unknown drug composition can be the cause  
237 of "hidden" allergens and may result in serious and sometimes even life-threatening symptoms as  
238 exemplified by a case of a heroin addict displaying an endophthalmitis believed to have resulted from  
239 fungal contaminants from his heroin as well as an anaphylactic reaction to lemon particles contaminating  
240 the drug used.<sup>57</sup>

241

242

## 243 ADVERSE REACTIONS TO ALCOHOLIC BEVERAGES

244 There are many causes for adverse reactions to alcohol. These reactions can be non-immunologic  
245 (pharmacologic) and immunogenic due to various ingredients of alcoholic beverages. Alcohol  
246 consumption, in addition, has an influence on the presentation of certain diseases and reactions to  
247 medications. The processing of alcoholic beverages and additives may contribute to the reactions to  
248 alcohol.

249

## 250 **Hereditary Enzyme Deficiency of the Alcohol Metabolism**

251 One of the most common adverse reactions to alcohol is the so-called “Asian Flush Syndrome”  
252 characterized by facial flushing, headache, nausea, dizziness, and cardiac palpitations after consumption  
253 of alcoholic beverages. There are two enzymatic steps to metabolize ethanol: The first is the production  
254 of acetaldehyde by the enzyme alcohol dehydrogenase (ADH) and the second is the breakdown of  
255 acetaldehyde by aldehyde dehydrogenase (ALDH). (figure 3). These enzymes are encoded by different  
256 genes, that occur in several variants (alleles). The enzymes encoded by these alleles can differ in the  
257 rate at which they metabolize alcohol.<sup>58</sup>

258 In the Asian Flush Syndrome, there is a mutation of ALDH2\*1 to ALDH2\*2 as the most common cause.<sup>59-</sup>  
259 <sup>61</sup> This mutation occurs in 560 million people (8%) of the world population. Its highest prevalence (35-  
260 45%) is in people of East-Asian descent, hence its name. The situation is even made worse if another  
261 mutation in the first ethanol metabolizing enzyme accompanies the problem: a mutated ADH, specifically  
262 ADH1B\*2.<sup>59</sup> This mutation also occurs more commonly in people of Asian descent. ADH1B\*2  
263 metabolizes ethanol fairly fast to acetaldehyde and if ALDH2 does not work the result is an increase in  
264 the acetaldehyde level. Acetaldehyde has been implicated in a marked increase in cancer of the upper  
265 digestive tract, especially esophageal cancer.<sup>61</sup> Although experiments have been performed to introduce  
266 the ALDH2 coding sequence into mice with the help of an adeno-associated virus (AAV) gene transfer to  
267 correct the deficiency state, the applications for humans may still take many years.<sup>62</sup>

268

## 269 **Immunogenic Reactions to Alcoholic Beverages**

270 In the allergy literature are reports of anaphylactic reactions to ethanol itself. <sup>63 64</sup> The studies mentioned  
271 are few, and usually involve the case history of sometimes poorly documented single patients. Skin tests  
272 with diluted acetic acid were used which were positive in the majority of patients and negative in controls.

273 However, almost all patients tolerated vinegar. In addition, provocation tests with ethanol, most of them  
274 blinded, were positive in all patients. It is rather difficult to explain the pathogenetic mechanism of these  
275 rather rare reactions. Newer research more concentrates on the multitude of components in alcoholic  
276 beverages.

277 One important allergen that occurs in alcoholic beverages is a lipid transfer protein (nsLTP) resistant to  
278 heat and acid.<sup>28</sup> Patients sensitized to nsLTP may be asymptomatic, but their reactions seem to be more  
279 severe when they are sensitized to the food nsLTP alone.<sup>31</sup> An nsLTP protein is present in grape *Vitis*  
280 *vinifera* (Vit v 1) and therefore in wine. nsLTP proteins are also present in beer deriving from different  
281 cereals that are germinated and heated to obtain malt. They occur in barley, *Hordeum sativa* and *vulgare*  
282 (Hor v 7k-nsLTP), wheat, *Triticum aestivum* and in maize *Zea mays* a. o.<sup>65</sup> Another nsLTP protein occurs  
283 in hops, *Humulus lupulus*, added for bitterness and flavor. These nsLTPs in sensitized patients, who  
284 consume wine or beer can lead to IgE-mediated reactions of different severity that may include  
285 anaphylaxis. Such allergic reactions can be amplified by concomitant exercise or use of non-steroidal  
286 anti-inflammatory drugs (NSAIDs).<sup>31</sup> Wheat containing beer, especially when consumed with additional  
287 wheat products, can lead to wheat-dependent exercise-induced anaphylaxis due to an antibody to wheat-  
288  $\gamma$ -gliadin.<sup>66 67</sup> In wheat beer (Weissbier) barley is mixed with 50 % of wheat malt. Newer proteomic and  
289 peptidomic analysis shows that it contains gluten epitopes and is therefore incompatible with a gluten-  
290 free diet for celiac patients.<sup>68</sup> In addition, Weissbier, due to the brewing technique, contains more yeast-  
291 derived products, mainly from *Saccharomyces spp.*, than other beers. An IgE-mediated yeast allergy is  
292 exceptionally rare. One of very few case reports establishes an Ig-E mediated sensitivity to yeast in beer,  
293 wine, and cider.<sup>69</sup> Yeast is added in the beer making process and occurs naturally in wine but may also  
294 be added to red wine must or to the juice from white wine. ImmunoCAP tests are available for  
295 *Saccharomyces* and for barley/malt. An interesting IgE-mediated allergy to red and white wine through  
296 oral sensitization to Hymenoptera venom was reported.<sup>70</sup> Hymenoptera venom can contaminate fresh  
297 pressed wine as stinging insects are attracted to sugars and alcohol in ripe grape bunches. The allergic

298 reaction occurred only to fresh pressed wine, and not to wine aged up to one year. In old wines the  
299 fermentation decomposes the venom. A rare report of anaphylaxis to gold tequila but not to white tequila  
300 was reported in a patient allergic to oak pollen.<sup>71</sup> Gold tequila is aged for months or years in oak barrels  
301 whereas clear tequila undergoes little to no aging.

302

### 303 **Discussion of the Clinical Implication of the Presence of Histamine in Alcohol**

304 The primary fermentation step produces alcohol and during the secondary fermentation biogenic amines,  
305 such as histamine, are formed.<sup>72</sup> The histamine content in beer, white and red wine is 176, 83, and 260  
306 mg/kg, respectively.<sup>73</sup> Scientific research of adverse reactions to ingested histamine, accused of causing  
307 symptoms of headache, flushing, diarrhea a.o. due to deficient ability to metabolize histamine,<sup>74</sup> did not  
308 reveal an isolated clinical picture.<sup>75</sup> Laboratory tests to study reactions to exogenous histamine are not  
309 reliable. Double-blind, placebo-controlled trials with histamine provocation triggered symptoms in healthy  
310 subjects.<sup>76</sup> A low histamine diet is of minimal benefit.<sup>77</sup> More scientific evidence is still required to define,  
311 diagnose, and treat symptoms of assumed adverse reactions to histamine.<sup>74 75</sup>

312

### 313 **Fining Agents in Wine**

314 Fining is a process in winemaking to remove small insoluble and colloidal particles and astringent  
315 compounds such as tannins. Fining agents are ovalbumin and lysozyme (extracted from hen's egg),  
316 cow's milk, casein, fish gelatin and isinglass (from swim bladders of sturgeon, cod, or hake). The fining  
317 process prevents later clouding of the wine, so that it remains stable for storage, transport, and  
318 temperature conditions.<sup>72</sup> Only wines with high concentration of fining agents resulted in positive skin  
319 prick tests in patients with a food allergy to the fining agent.<sup>78 79</sup> A preliminary study with immunoblotting  
320 to detect and quantify ovalbumin and casein in bottled wine showed the samples to be allergen free.<sup>80</sup>  
321 Another study reports negligible residual food allergens in wine.<sup>81</sup> Although there is concern regarding

322 labeling of wines for food-allergic patients in many countries, these studies make a reaction to fining  
323 agents in IgE-mediated food allergic patients either rare or highly unlikely. Many wine-producing countries  
324 will run more large-scale studies to ensure the safety of handling the removal process of fining agents.

325

## 326 **Sulfites in Wine**

327 Small amounts of sulfites occur naturally in all wines. Sulfites are added during the winemaking process  
328 to arrest fermentation, to act as preservatives and to prevent spoilage from oxidation and protect from  
329 bacteria. Sulfites are at much higher concentration in white than in red wine.<sup>72</sup> Previous studies indicated  
330 that wine consumption was associated with worsening of asthma symptoms, but high-and low-sulfite wine  
331 challenges did not support a role for sulfites in stable asthmatics.<sup>82</sup> However, asthma patients, mostly  
332 with IgE-independent steroid-dependent asthma, in as many as 5% may react with mild wheezing or  
333 severe bronchoconstriction to sulfite-containing beverages.<sup>83</sup> The mechanism of sulfite-induced asthma  
334 is controversial. An IgE-mechanism has been suspected but not proven. Debated have also been a  
335 cholinergic reflex, a partial deficiency of the sulfite-oxidase enzyme, responsible for the final oxidizing of  
336 sulfite to inactive sulfate, and a kinin mechanism. Reaction to sulfites seems to be a nonspecific response  
337 and specific IgE antibodies to sulfites have not been identified.<sup>84</sup>

338

339

## 340 **Specific alcohol-related Effects on Medical Conditions**

341 Patients with Aspirin Exacerbated Respiratory Disease (AERD) and Chronic Rhinosinusitis (CRS) can  
342 experience respiratory reactions with alcohol ingestion.<sup>85</sup> In AERD, the severity of aspirin-induced  
343 reactions during aspirin challenge correlated with the severity of the alcohol-induced reaction. As patients



344 with AERD have a higher excretion of urinary Leukotrienes (LTs) an LT-dependent mechanism may  
345 underlie the alcohol-induced respiratory reactions.

346 **Systemic Contact dermatitis** Ethanol is used as topical penetration enhancer in transdermal  
347 medications as it removes lipids from the skin. Use of such “patches” over a prolonged period of time can  
348 lead to ethanol sensitization resulting in a delayed (8 hours) cutaneous reaction.<sup>86</sup>  
349 Patients with **Chronic Urticaria** often notice an exacerbation after ingestion of alcohol.<sup>87</sup>

350 **Rosacea** flushing, among other factors, is known to be triggered by alcohol, recently thought to be caused  
351 by neuronal signaling.<sup>88</sup> In patients with **Hodgkin lymphoma** pain at the site of bone or lymph node  
352 involvement may appear minutes after ingestion. This alcohol-related pain is highly specific for the  
353 diagnosis and occurs in 1.5 – 5% percent of patients<sup>89</sup>, the mechanism is unknown. One of the factors  
354 provoking flushing in **Carcinoid Syndrome** is alcohol.<sup>90</sup>

355 The exacerbation of symptoms of **Mastocytosis** has been thought, amongst other factors, to be  
356 influenced by alcohol due to its content of histamine.<sup>91</sup>

357

## 358 **Alcohol-Medication Interactions**

359 Many medication reactions involve an interference with the activity of ADH increasing the level of  
360 acetaldehyde which causes facial flushing, nausea, vomiting, tachycardia, and hypotension. In this  
361 category are medications such as **Disulfiram**, **Cephalosporines** with a methylthiotetrazole side chain  
362 and **Chlorpropamide**.<sup>91-93</sup> Another enzyme system that likely plays a role in alcohol-medication  
363 interactions is the P450 reductase and the CYP2E1.<sup>94</sup>

364 However, not all disulfiram-like reactions are yet clarified. One such reaction is a disulfiram-like reaction  
365 to metronidazole and other nitroimidazoles in patients consuming alcohol. The interaction between  
366 metronidazole and alcohol does not occur in all patients, suggesting an individual susceptibility.<sup>92</sup> Other  
367 interesting reactions may occur to the topical calcineurin inhibitors, **Tacrolimus** and **Pimecrolimus**. Five

368 to ten minutes after a local application not only the treated area can become erythematous but flushing  
369 of healthy skin, for example the face, may occur.<sup>92</sup> An unusual reaction in a patient that tolerated topical  
370 tacrolimus for years occurred when **Dupilumab** was started.<sup>95</sup> Future research will reveal more  
371 information on alcohol-related medication reactions.

372

373

## 374 CONCLUSIONS

375 In the field of Allergy, much has already been discovered concerning allergies to pollen, food and plant  
376 products. However, the investigations of (illicit) drug allergies seem to be lagging behind. This review  
377 highlights what is known about allergies and other adverse reactions to cannabis, cocaine, opiates,  
378 opioids and alcohol. In addition, several hurdles, and points of attention specific to this field of research  
379 are discussed in the hope to facilitate future qualitative research and help progress our knowledge about  
380 (illicit) drug allergy.

381 Apart from a patient's reticence to discuss their drug use, it is also important to keep in mind that many  
382 drugs induce a mind-altering state with different sensations of time and space as well as a varying degree  
383 of retrograde amnesia. Thus, the patient might experience symptoms differently impacting for example  
384 the accuracy of the reported time between contact and onset of symptoms as well as perceived duration  
385 of symptoms; details which are of paramount importance in allergy history taking.

386 This review shows that cocaine use should be systematically considered in the case of asthma  
387 exacerbations. Cannabis, cocaine or heroin use must be considered in cases of acute respiratory  
388 symptoms or asthma exacerbation in young people and practitioners must help illicit substance users to  
389 stop their consumption.<sup>40 96</sup>

390 It is necessary to find reliable diagnostic methods based on *in vivo* and *in vitro* tests using extracts of the  
391 natural plant source or recombinant proteins in a large series of habitual heroin, cocaine and cannabis

392 consumers and atopic and non-atopic controls. In patients sensitized to these drugs, antibodies can be  
393 measured for many years, which could have legal and forensic implications, and could allow changes in  
394 drugs like opium and cocaine-derived anesthetics in patients about to undergo surgery. In closing it is  
395 hoped that the outlined factors involved in adverse reactions to alcohol will support a stepwise analysis  
396 of situations seen in the clinic.

397

398 **FIGURES AND TABLES**

399

400 TABLE 1: Allergens from Cannabis sativa (Can s) indexed in the Allergen list of the IUIS.

IUIS nomenclature	Allergen class Genbank Nucl Genbank Prot	Molecular weight (kDa)	Available from	Reference
Can s 2	<b>Profilin</b> XM030636604.1 XP030492464.1	14	H.P. Rihs	29
Can s 3	<b>nsLTP</b> HE972341 CCK33472	9	H.P. Rihs	11 28
Can s 4	<b>OEEP2</b> XM030626708.1 XP030482568.1	27.3	H.P. Rihs	27
Can s 5	<b>Bet v 1</b> <b>homologue</b> JN6792251.1 AFN42528.1	17.7	H.P. Rihs	29

401

402 **FIGURE 1**




403

404 *Legend: \*opiates derive from natural whereas opioids from synthetic sources.*

405

406




408

409 *Legend: Proposed stepwise diagnostic approach for cannabis allergy. Adapted from Decuyper et al. <sup>31</sup>.*

410

411



413  
414 Namrata Chhabra (2015); ‘Alcohol-induced metabolic alterations- a case-based discussion’: Our  
415 Biochemistry; slide 4(64); [https://www2.slideshare.net/namarta28/alcohol-induced-metabolic-](https://www2.slideshare.net/namarta28/alcohol-induced-metabolic-alterations-a-case-based-discussion/6)  
416 [alterations-a-case-based-discussion/6](https://www2.slideshare.net/namarta28/alcohol-induced-metabolic-alterations-a-case-based-discussion/6)

417  
418 Legend: Column 1 gives an overview of known Cannabis allergens, listed with the name assigned  
419 by the International Union of Immunological Societies (IUIS). Column 2 lists the corresponding  
420 sequence data of the GenBank for the Nucleotide (Nucl) and the Protein (Prot). The GenBank  
421 is a part of the International Nucleotide Sequence Database Collaboration (INSDC).

## REFERENCES

1. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. *Br J Clin Pharmacol* 2011;71(5):684-700. doi: 10.1111/j.1365-2125.2010.03774.x [published Online First: 2011/04/13]
2. Demoly P, Castells M. Important questions in drug allergy and hypersensitivity: consensus papers from the 2018 AAAAI/WAO international drug allergy symposium. *World Allergy Organ J* 2018;11(1):42. doi: 10.1186/s40413-018-0224-1 [published Online First: 2019/01/02]
3. Mustafa SS, Conn K, Ramsey A. Comparing Direct Challenge to Penicillin Skin Testing for the Outpatient Evaluation of Penicillin Allergy: A Randomized Controlled Trial. *J Allergy Clin Immunol Pract* 2019;7(7):2163-70. doi: 10.1016/j.jaip.2019.05.037 [published Online First: 2019/06/07]
4. Khan DA, Solensky R. Drug allergy. *J Allergy Clin Immunol* 2010;125(2 Suppl 2):S126-37. doi: 10.1016/j.jaci.2009.10.028 [published Online First: 2010/03/05]
5. Chiriac AM, Demoly P. Drug allergy diagnosis. *Immunol Allergy Clin North Am* 2014;34(3):461-71, vii. doi: 10.1016/j.iac.2014.03.002 [published Online First: 2014/07/16]
6. Ramsey A, Sheikh A. Innovations in Health Care Delivery: Drug Allergy. *J Allergy Clin Immunol Pract* 2019;7(7):2143-50. doi: 10.1016/j.jaip.2019.04.050 [published Online First: 2019/05/21]
7. Crime UNOoDa. World Drug Report. 2020
8. Amin MR, Ali DW. Pharmacology of Medical Cannabis. *Adv Exp Med Biol* 2019;1162:151-65. doi: 10.1007/978-3-030-21737-2\_8 [published Online First: 2019/07/25]
9. Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response. *Epilepsy Behav* 2014;41:277-82. doi: 10.1016/j.yebeh.2014.08.135 [published Online First: 2014/10/06]
10. Organization WH. The health and social effects of nonmedical cannabis use. ISBN 978 92 4 151024 0 2016
11. Decuyper, II, Van Gasse AL, Faber MA, et al. Exploring the Diagnosis and Profile of Cannabis Allergy. *J Allergy Clin Immunol Pract* 2019;7(3):983-89 e5. doi: 10.1016/j.jaip.2018.09.017 [published Online First: 2018/10/03]
12. Armentia A, Castrodeza J, Ruiz-Munoz P, et al. Allergic hypersensitivity to cannabis in patients with allergy and illicit drug users. *Allergol Immunopathol (Madr)* 2011;39(5):271-9. doi: 10.1016/j.aller.2010.09.008 [published Online First: 2011/01/29]
13. Rihs HP, Armentia A, Sander I, et al. IgE-binding properties of a recombinant lipid transfer protein from Cannabis sativa. *Ann Allergy Asthma Immunol* 2014;113(2):233-4. doi: 10.1016/j.anai.2014.05.022 [published Online First: 2014/06/24]
14. Nayak AP, Green BJ, Sussman G, et al. Characterization of Cannabis sativa allergens. *Ann Allergy Asthma Immunol* 2013;111(1):32-7. doi: 10.1016/j.anai.2013.04.018 [published Online First: 2013/06/29]
15. Yazulla S. Endocannabinoids in the retina: from marijuana to neuroprotection. *Prog Retin Eye Res* 2008;27(5):501-26. doi: 10.1016/j.preteyeres.2008.07.002 [published Online First: 2008/08/30]
16. Tashkin DP, Baldwin GC, Sarafian T, et al. Respiratory and immunologic consequences of marijuana smoking. *J Clin Pharmacol* 2002;42(S1):71S-81S. doi: 10.1002/j.1552-4604.2002.tb06006.x [published Online First: 2002/11/05]
17. Tashkin DP, Coulson AH, Clark VA, et al. Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers. *Am Rev Respir Dis* 1987;135(1):209-16. doi: 10.1164/arrd.1987.135.1.209 [published Online First: 1987/01/01]
18. Zeiger JS, Silvers WS, Winders TA, et al. Cannabis attitudes and patterns of use among followers of the Allergy & Asthma Network. *Ann Allergy Asthma Immunol* 2021 doi: 10.1016/j.anai.2021.01.014 [published Online First: 2021/01/20]
19. Decuyper, II, Van Gasse A, Faber MA, et al. Occupational cannabis exposure and allergy risks. *Occup Environ Med* 2019;76(2):78-82. doi: 10.1136/oemed-2018-105302 [published Online First: 2018/12/17]

- 469 20. Vanhove W, Cuypers E, Bonneure AJ, et al. The Health Risks of Belgian Illicit Indoor Cannabis Plantations. *J*  
470 *Forensic Sci* 2018;63(6):1783-89. doi: 10.1111/1556-4029.13788 [published Online First: 2018/04/11]
- 471 21. Ebo DG, Swerts S, Sabato V, et al. New food allergies in a European non-Mediterranean region: is Cannabis  
472 sativa to blame? *Int Arch Allergy Immunol* 2013;161(3):220-8. doi: 10.1159/000346721 [published  
473 Online First: 2013/04/04]
- 474 22. Majmudar V, Azam NA, Finch T. Contact urticaria to Cannabis sativa. *Contact Dermatitis* 2006;54(2):127. doi:  
475 10.1111/j.0105-1873.2006.0560h.x [published Online First: 2006/02/21]
- 476 23. Rojas Perez-Ezquerria P, Sanchez-Morillas L, Davila-Ferandez G, et al. Contact urticaria to Cannabis sativa due  
477 to a lipid transfer protein (LTP). *Allergol Immunopathol (Madr)* 2015;43(2):231-3. doi:  
478 10.1016/j.aller.2013.10.002 [published Online First: 2014/03/25]
- 479 24. Williams C, Thompstone J, Wilkinson M. Work-related contact urticaria to Cannabis sativa. *Contact*  
480 *Dermatitis* 2008;58(1):62-3. doi: 10.1111/j.1600-0536.2007.01169.x [published Online First:  
481 2007/12/25]
- 482 25. Angelina A, Perez-Diego M, Lopez-Abente J, et al. The Role of Cannabinoids in Allergic Diseases: Collegium  
483 Internationale Allergologicum (CIA) Update 2020. *Int Arch Allergy Immunol* 2020;181(8):565-84. doi:  
484 10.1159/000508989 [published Online First: 2020/06/12]
- 485 26. Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and  
486 respiratory complications: a systematic review. *Arch Intern Med* 2007;167(3):221-8. doi:  
487 10.1001/archinte.167.3.221 [published Online First: 2007/02/14]
- 488 27. Decuyper, II, Rihs HP, Mertens CH, et al. A new cannabis allergen in Northwestern Europe: The oxygen-  
489 evolving enhancer protein 2 (OEEP2). *J Allergy Clin Immunol Pract* 2020;8(7):2421-24 e2. doi:  
490 10.1016/j.jaip.2020.03.031 [published Online First: 2020/04/17]
- 491 28. Gamboa P, Sanchez-Monge R, Sanz ML, et al. Sensitization to Cannabis sativa caused by a novel allergenic  
492 lipid transfer protein, Can s 3. *J Allergy Clin Immunol* 2007;120(6):1459-60. doi:  
493 10.1016/j.jaci.2007.07.052 [published Online First: 2007/09/21]
- 494 29. D.G. Ebo IID, H.P. Rihs, C.H. Mertens, A.L. Van Gasse, M.L. Van der Poorten, L. De Puyseleyn, M. A. Faber, M.  
495 M. Hagendorens, C.H. Bridts, V. Sabato, J. Elst. IgE-binding and mast cell activating capacity of the  
496 homologue of the major birch pollen allergen and profilin from Cannabis sativa. *J Allergy Clin Immunol*  
497 *Pract* 2021;accepted
- 498 30. Faber MA, Sabato V, Bridts CH, et al. Clinical relevance of the Hevea brasiliensis lipid transfer protein Hev b  
499 12. *J Allergy Clin Immunol* 2015;135(6):1645-8. doi: 10.1016/j.jaci.2014.12.1919 [published Online First:  
500 2015/02/05]
- 501 31. Decuyper, II, Rihs HP, Van Gasse AL, et al. Cannabis allergy: what the clinician needs to know in 2019. *Expert*  
502 *Rev Clin Immunol* 2019;15(6):599-606. doi: 10.1080/1744666X.2019.1600403 [published Online First:  
503 2019/04/05]
- 504 32. Armentia A, Herrero M, Martin-Armentia B, et al. Molecular diagnosis in cannabis allergy. *J Allergy Clin*  
505 *Immunol Pract* 2014;2(3):351-2. doi: 10.1016/j.jaip.2014.01.015 [published Online First: 2014/05/09]
- 506 33. Watson ES, Murphy JC, Turner CE. Allergenic properties of naturally occurring cannabinoids. *J Pharm Sci*  
507 1983;72(8):954-5. doi: 10.1002/jps.2600720831 [published Online First: 1983/08/01]
- 508 34. Green BJ, Couch JR, Lemons AR, et al. Microbial hazards during harvesting and processing at an outdoor  
509 United States cannabis farm. *J Occup Environ Hyg* 2018;15(5):430-40. doi:  
510 10.1080/15459624.2018.1432863 [published Online First: 2018/01/26]
- 511 35. Engler DB, Malick AA, Saraf SK, et al. Severe Marijuana Allergy Controlled with Omalizumab. *Journal of*  
512 *Allergy and Clinical Immunology* 2013;131(2):AB215. doi: 10.1016/j.jaci.2012.12.1437
- 513 36. Raj Kumar NG. A case of bronchial asthma and allergic rhinitis exacerbated during Cannabis pollination and  
514 subsequently controlled by subcutaneous immunotherapy. *Indian Journal of Allergy, Asthma and*  
515 *Immunology* 2013;27(2):143-46.



- 516 37. Armentia A, Martin-Armentia B, Martin-Armentia S, et al. Cocaine Allergy in Drug-Dependent Patients and  
517 Allergic People. *J Allergy Clin Immunol Pract* 2018;6(1):201-07. doi: 10.1016/j.jaip.2017.06.013  
518 [published Online First: 2017/09/03]
- 519 38. Self TH, Shah SP, March KL, et al. Asthma associated with the use of cocaine, heroin, and marijuana: A review  
520 of the evidence. *J Asthma* 2017;54(7):714-22. doi: 10.1080/02770903.2016.1259420 [published Online  
521 First: 2016/11/20]
- 522 39. Ettinger NA, Albin RJ. A review of the respiratory effects of smoking cocaine. *Am J Med* 1989;87(6):664-8.  
523 doi: 10.1016/s0002-9343(89)80401-2 [published Online First: 1989/12/01]
- 524 40. Underner M, Perriot J, Peiffer G, et al. [Asthma and cocaine use]. *Rev Mal Respir* 2019;36(5):610-24. doi:  
525 10.1016/j.rmr.2018.08.026 [published Online First: 2019/06/16]
- 526 41. Castro-Villamor MA, de las Heras P, Armentia A, et al. Cocaine-induced severe angioedema and urticaria. *Ann*  
527 *Emerg Med* 1999;34(2):296-7. doi: 10.1016/s0196-0644(99)70257-x [published Online First: 1999/07/29]
- 528 42. Ribeiro M, Trevizol AP, Frajzinger R, et al. Adulterants in crack cocaine in Brazil. *Trends Psychiatry Psychother*  
529 2019;41(2):186-90. doi: 10.1590/2237-6089-2017-0143 [published Online First: 2019/07/18]
- 530 43. Brunt TM, van den Berg J, Pennings E, et al. Adverse effects of levamisole in cocaine users: a review and risk  
531 assessment. *Arch Toxicol* 2017;91(6):2303-13. doi: 10.1007/s00204-017-1947-4 [published Online First:  
532 2017/03/21]
- 533 44. Stepanovic B, Sommerfield D, Lucas M, et al. An update on allergy and anaphylaxis in pediatric anesthesia.  
534 *Paediatr Anaesth* 2019;29(9):892-900. doi: 10.1111/pan.13703 [published Online First: 2019/08/06]
- 535 45. Caron AB. Allergy to multiple local anesthetics. *Allergy Asthma Proc* 2007;28(5):600-1. doi:  
536 10.2500/aap2007.28.3035 [published Online First: 2007/11/24]
- 537 46. Jussi L, Lammintausta K. Sources of sensitization, cross-reactions, and occupational sensitization to topical  
538 anaesthetics among general dermatology patients. *Contact Dermatitis* 2009;60(3):150-4. doi:  
539 10.1111/j.1600-0536.2008.01499.x [published Online First: 2009/03/06]
- 540 47. Swerts S, Van Gasse A, Leysen J, et al. Allergy to illicit drugs and narcotics. *Clin Exp Allergy* 2014;44(3):307-18.  
541 doi: 10.1111/cea.12177 [published Online First: 2014/03/05]
- 542 48. Garvey LH, Ebo DG, Mertes PM, et al. An EAACI position paper on the investigation of perioperative  
543 immediate hypersensitivity reactions. *Allergy* 2019;74(10):1872-84. doi: 10.1111/all.13820 [published  
544 Online First: 2019/04/10]
- 545 49. Baldo BA, Pham NH. Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the  
546 two. *Anaesth Intensive Care* 2012;40(2):216-35. doi: 10.1177/0310057X1204000204 [published Online  
547 First: 2012/03/16]
- 548 50. Armentia A, Pineda F, Palacios R, et al. Utility of opium seed extract tests in preventing hypersensitivity  
549 reactions during surgery. *Allergol Immunopathol (Madr)* 2014;42(1):56-63. doi:  
550 10.1016/j.aller.2012.08.010 [published Online First: 2013/01/22]
- 551 51. Armentia A, Pineda F, Martin-Armentia B, et al. A useful method to detect opioid allergies. *J Allergy Clin*  
552 *Immunol Pract* 2015;3(5):829-30. doi: 10.1016/j.jaip.2015.05.031 [published Online First: 2015/09/13]
- 553 52. Van Gasse AL, Hagendorens MM, Sabato V, et al. IgE to Poppy Seed and Morphine Are Not Useful Tools to  
554 Diagnose Opiate Allergy. *J Allergy Clin Immunol Pract* 2015;3(3):396-9. doi: 10.1016/j.jaip.2014.12.002  
555 [published Online First: 2015/05/10]
- 556 53. Volcheck GW, Mertes PM. Local and general anesthetics immediate hypersensitivity reactions. *Immunol*  
557 *Allergy Clin North Am* 2014;34(3):525-46, viii. doi: 10.1016/j.iac.2014.03.004 [published Online First:  
558 2014/07/16]
- 559 54. Lansu K, Karpiak J, Liu J, et al. In silico design of novel probes for the atypical opioid receptor MRGPRX2. *Nat*  
560 *Chem Biol* 2017;13(5):529-36. doi: 10.1038/nchembio.2334 [published Online First: 2017/03/14]
- 561 55. Ebo DG, Van der Poorten ML, Elst J, et al. Immunoglobulin E cross-linking or MRGPRX2 activation: clinical  
562 insights from rocuronium hypersensitivity. *Br J Anaesth* 2021;126(1):e27-e29. doi:  
563 10.1016/j.bja.2020.10.006 [published Online First: 2020/11/07]

- 564 56. Ebo DG, Bridts CH, Mertens CH, et al. Principles, potential, and limitations of ex vivo basophil activation by  
565 flow cytometry in allergology: A narrative review. *J Allergy Clin Immunol* 2020 doi:  
566 10.1016/j.jaci.2020.10.027 [published Online First: 2020/11/06]
- 567 57. Armentia A, Pineda F, Martin-Armentia B, et al. Endophthalmitis related to lemon allergy in a heroin addict.  
568 *Allergol Immunopathol (Madr)* 2016;44(5):472-4. doi: 10.1016/j.aller.2015.12.003 [published Online  
569 First: 2016/04/19]
- 570 58. Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde  
571 dehydrogenase variants. *Alcohol Res Health* 2007;30(1):5-13. [published Online First: 2007/08/28]
- 572 59. Edenberg HJ, McClintick JN. Alcohol Dehydrogenases, Aldehyde Dehydrogenases, and Alcohol Use Disorders:  
573 A Critical Review. *Alcohol Clin Exp Res* 2018;42(12):2281-97. doi: 10.1111/acer.13904 [published Online  
574 First: 2018/10/16]
- 575 60. Cederbaum AI. Alcohol metabolism. *Clin Liver Dis* 2012;16(4):667-85. doi: 10.1016/j.cld.2012.08.002  
576 [published Online First: 2012/10/30]
- 577 61. Gross ER, Zambelli VO, Small BA, et al. A personalized medicine approach for Asian Americans with the  
578 aldehyde dehydrogenase 2\*2 variant. *Annu Rev Pharmacol Toxicol* 2015;55:107-27. doi:  
579 10.1146/annurev-pharmtox-010814-124915 [published Online First: 2014/10/09]
- 580 62. Matsumura Y, Stiles KM, Reid J, et al. Gene Therapy Correction of Aldehyde Dehydrogenase 2 Deficiency.  
581 *Mol Ther Methods Clin Dev* 2019;15:72-82. doi: 10.1016/j.omtm.2019.08.004 [published Online First:  
582 2019/10/28]
- 583 63. Rajan J KD. Remission of Anaphylactic Reaction to Alcohol. *J Aller Ther* 2010;1:104 doi: doi:10.4172/2155-  
584 6121.1000104
- 585
- 586 64. Fernando SL, Clarke LR. Two Case Reports of Life-Threatening Ethanol-Induced Anaphylaxis. *Case Rep*  
587 *Dermatol* 2009;1(1):1-6. doi: 10.1159/000209154 [published Online First: 2009/01/01]
- 588 65. Quercia O, Zoccatelli G, Stefanini GF, et al. Allergy to beer in LTP-sensitized patients: beers are not all the  
589 same. *Allergy* 2012;67(9):1186-9. doi: 10.1111/j.1398-9995.2012.02872.x [published Online First:  
590 2012/08/01]
- 591 66. Beezhold DH, Hickey VL, Kostyal DA, et al. Lipid transfer protein from Hevea brasiliensis (Hev b 12), a cross-  
592 reactive latex protein. *Ann Allergy Asthma Immunol* 2003;90(4):439-45. doi: 10.1016/S1081-  
593 1206(10)61830-3 [published Online First: 2003/05/02]
- 594 67. Morita E, Yamamura Y, Mihara S, et al. Food-dependent exercise-induced anaphylaxis: a report of two cases  
595 and determination of wheat-gamma-gliadin as the presumptive allergen. *Br J Dermatol*  
596 2000;143(5):1059-63. doi: 10.1046/j.1365-2133.2000.03844.x [published Online First: 2000/11/09]
- 597 68. Picariello G, Mamone G, Cutignano A, et al. Proteomics, peptidomics, and immunogenic potential of wheat  
598 beer (Weissbier). *J Agric Food Chem* 2015;63(13):3579-86. doi: 10.1021/acs.jafc.5b00631 [published  
599 Online First: 2015/03/21]
- 600 69. Bansal RA, Tadros S, Bansal AS. Beer, Cider, and Wine Allergy. *Case Reports Immunol* 2017;2017:7958924.  
601 doi: 10.1155/2017/7958924 [published Online First: 2017/04/12]
- 602 70. Armentia A, Pineda F, Fernandez S. Wine-induced anaphylaxis and sensitization to hymenoptera venom. *N*  
603 *Engl J Med* 2007;357(7):719-20. doi: 10.1056/NEJMc063424 [published Online First: 2007/08/19]
- 604 71. Coons BD, White K. Anaphylaxis to gold tequila. *Ann Allergy Asthma Immunol* 2013;111(1):70-1. doi:  
605 10.1016/j.anai.2013.05.001 [published Online First: 2013/06/29]
- 606 72. Wuthrich B. Allergic and intolerance reactions to wine. *Allergol Select* 2018;2(1):80-88. doi:  
607 10.5414/ALX01420E [published Online First: 2018/09/01]
- 608 73. Comas-Baste O, Sanchez-Perez S, Veciana-Nogues MT, et al. Histamine Intolerance: The Current State of the  
609 Art. *Biomolecules* 2020;10(8) doi: 10.3390/biom10081181 [published Online First: 2020/08/23]

- 610 74. Maintz L, Novak N. Histamine and histamine intolerance. *Am J Clin Nutr* 2007;85(5):1185-96. doi:  
611 10.1093/ajcn/85.5.1185 [published Online First: 2007/05/11]
- 612 75. Reese I, Ballmer-Weber B, Beyer K, et al. German guideline for the management of adverse reactions to  
613 ingested histamine: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI),  
614 the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German  
615 Association of Allergologists (AeDA), and the Swiss Society for Allergology and Immunology (SGAI).  
616 *Allergo J Int* 2017;26(2):72-79. doi: 10.1007/s40629-017-0011-5 [published Online First: 2017/03/28]
- 617 76. Siebenhaar F, Melde A, Magerl M, et al. Histamine intolerance in patients with chronic spontaneous  
618 urticaria. *J Eur Acad Dermatol Venereol* 2016;30(10):1774-77. doi: 10.1111/jdv.13778 [published Online  
619 First: 2016/10/21]
- 620 77. Cornillier H, Giraudeau B, Samimi M, et al. Effect of Diet in Chronic Spontaneous Urticaria: A Systematic  
621 Review. *Acta Derm Venereol* 2019;99(2):127-32. doi: 10.2340/00015555-3015 [published Online First:  
622 2018/08/08]
- 623 78. Kirschner S, Belloni B, Kugler C, et al. Allergenicity of wine containing processing aids: a double-blind,  
624 placebo-controlled food challenge. *J Investig Allergol Clin Immunol* 2009;19(3):210-7. [published Online  
625 First: 2009/07/21]
- 626 79. Vassilopoulou E, Karathanos A, Siragakis G, et al. Risk of allergic reactions to wine, in milk, egg and fish-  
627 allergic patients. *Clin Transl Allergy* 2011;1(1):10. doi: 10.1186/2045-7022-1-10 [published Online First:  
628 2011/01/01]
- 629 80. Meyer P, Zanetti S. Detection of Traces of Ovalbumin and Casein in White and Red Wines by Quantitative  
630 Western Blotting. *J Food Sci* 2015;80(9):T2102-9. doi: 10.1111/1750-3841.12990 [published Online First:  
631 2015/08/12]
- 632 81. Rolland JM, Apostolou E, Deckert K, et al. Potential food allergens in wine: double-blind, placebo-controlled  
633 trial and basophil activation analysis. *Nutrition* 2006;22(9):882-8. doi: 10.1016/j.nut.2006.06.002  
634 [published Online First: 2006/08/25]
- 635 82. Vally H, Thompson PJ, Misso NL. Changes in bronchial hyperresponsiveness following high- and low-sulphite  
636 wine challenges in wine-sensitive asthmatic patients. *Clin Exp Allergy* 2007;37(7):1062-6. doi:  
637 10.1111/j.1365-2222.2007.02747.x [published Online First: 2007/06/22]
- 638 83. Bush RK, Taylor SL, Holden K, et al. Prevalence of sensitivity to sulfiting agents in asthmatic patients. *Am J*  
639 *Med* 1986;81(5):816-20. doi: 10.1016/0002-9343(86)90351-7 [published Online First: 1986/11/01]
- 640 84. Bush RK, Taylor SL, Busse W. A critical evaluation of clinical trials in reactions to sulfites. *J Allergy Clin*  
641 *Immunol* 1986;78(1 Pt 2):191-202. doi: 10.1016/0091-6749(86)90012-6 [published Online First:  
642 1986/07/01]
- 643 85. Cardet JC WA, Barrett NA, Feldweg AM, Pickner PG, Savage J et al. Alcohol-induced respiratory symptoms are  
644 common in patients with aspirin exacerbated respiratory disease. *J Allergy Clin Immunol In Practice*  
645 2014;2(2):208-213. doi.org/10.1016/j.jaip.2013.12.003.
- 646 86. Wolverson W, Gada S. Systemic contact dermatitis to ethanol. *J Allergy Clin Immunol Pract* 2013;1(2):195-6.  
647 doi: 10.1016/j.jaip.2012.11.007 [published Online First: 2014/02/26]
- 648 87. Hon KL, Leung AKC, Ng WGG, et al. Chronic Urticaria: An Overview of Treatment and Recent Patents. *Recent*  
649 *Pat Inflamm Allergy Drug Discov* 2019;13(1):27-37. doi: 10.2174/1872213X13666190328164931  
650 [published Online First: 2019/03/30]
- 651 88. Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. *F1000Res* 2018;7 doi:  
652 10.12688/f1000research.16537.1 [published Online First: 2019/01/12]
- 653 89. Bobrove AM. Alcohol-related pain and Hodgkin's disease. *West J Med* 1983;138(6):874-5. [published Online  
654 First: 1983/06/01]
- 655 90. Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology  
656 and treatment. *Clinics (Sao Paulo)* 2018;73(suppl 1):e490s. doi: 10.6061/clinics/2018/e490s [published  
657 Online First: 2018/08/23]

- 658 91. Valent P, Akin C, Gleixner KV, et al. Multidisciplinary Challenges in Mastocytosis and How to Address with  
659 Personalized Medicine Approaches. *Int J Mol Sci* 2019;20(12) doi: 10.3390/ijms20122976 [published  
660 Online First: 2019/06/21]
- 661 92. Borja-Oliveira C. Alcohol-medication interactions: The acetaldehyde syndrome. *J Pharmacovigilance* 2014;2:5  
662 doi: 10.4172/2329-6887.1000145
- 663 93. Mergenhagen KA, Wattengel BA, Skelly MK, et al. Fact versus Fiction: a Review of the Evidence behind  
664 Alcohol and Antibiotic Interactions. *Antimicrob Agents Chemother* 2020;64(3) doi: 10.1128/AAC.02167-  
665 19 [published Online First: 2019/12/25]
- 666 94. Weathermon R, Crabb DW. Alcohol and medication interactions. *Alcohol Res Health* 1999;23(1):40-54.  
667 [published Online First: 2000/07/13]
- 668 95. Igelman SJ, Na C, Simpson EL. Alcohol-induced facial flushing in a patient with atopic dermatitis treated with  
669 dupilumab. *JAAD Case Rep* 2020;6(2):139-40. doi: 10.1016/j.jdc.2019.12.002 [published Online First:  
670 2020/02/06]
- 671 96. Underner M, Peiffer G, Perriot J, et al. [Asthma and cannabis, cocaine or heroin use]. *Rev Mal Respir*  
672 2020;37(7):572-89. doi: 10.1016/j.rmr.2020.06.004 [published Online First: 2020/07/13]
- 673